215 related articles for article (PubMed ID: 15146434)
1. Antiangiogenic effects of anti-tumor necrosis factor alpha therapy with infliximab in psoriatic arthritis.
Cañete JD; Pablos JL; Sanmartí R; Mallofré C; Marsal S; Maymó J; Gratacós J; Mezquita J; Mezquita C; Cid MC
Arthritis Rheum; 2004 May; 50(5):1636-41. PubMed ID: 15146434
[TBL] [Abstract][Full Text] [Related]
2. Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: a prospective single-centre study.
Goedkoop AY; Kraan MC; Picavet DI; de Rie MA; Teunissen MB; Bos JD; Tak PP
Arthritis Res Ther; 2004; 6(4):R326-34. PubMed ID: 15225368
[TBL] [Abstract][Full Text] [Related]
3. Resolution of endothelial activation and down-regulation of Tie2 receptor in psoriatic skin after infliximab therapy.
Markham T; Mullan R; Golden-Mason L; Rogers S; Bresnihan B; Fitzgerald O; Fearon U; Veale DJ
J Am Acad Dermatol; 2006 Jun; 54(6):1003-12. PubMed ID: 16713454
[TBL] [Abstract][Full Text] [Related]
4. Reduction of synovial sublining layer inflammation and proinflammatory cytokine expression in psoriatic arthritis treated with methotrexate.
Kane D; Gogarty M; O'leary J; Silva I; Bermingham N; Bresnihan B; Fitzgerald O
Arthritis Rheum; 2004 Oct; 50(10):3286-95. PubMed ID: 15476228
[TBL] [Abstract][Full Text] [Related]
5. Analysis of vascular gene expression in arthritic synovium by laser-mediated microdissection.
Hashimoto A; Tarner IH; Bohle RM; Gaumann A; Manetti M; Distler O; Steinmeyer J; Ulfgren AK; Schulz A; Gay S; Müller-Ladner U; Neumann E
Arthritis Rheum; 2007 Apr; 56(4):1094-105. PubMed ID: 17393418
[TBL] [Abstract][Full Text] [Related]
6. Angiopoietins, growth factors, and vascular morphology in early arthritis.
Fearon U; Griosios K; Fraser A; Reece R; Emery P; Jones PF; Veale DJ
J Rheumatol; 2003 Feb; 30(2):260-8. PubMed ID: 12563678
[TBL] [Abstract][Full Text] [Related]
7. Vascular endothelial growth factors C and D and their VEGFR-2 and 3 receptors in blood and lymphatic vessels in healthy and arthritic synovium.
Paavonen K; Mandelin J; Partanen T; Jussila L; Li TF; Ristimaki A; Alitalo K; Konttinen YT
J Rheumatol; 2002 Jan; 29(1):39-45. PubMed ID: 11824969
[TBL] [Abstract][Full Text] [Related]
8. Early effects of tumour necrosis factor alpha blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis.
Goedkoop AY; Kraan MC; Teunissen MB; Picavet DI; de Rie MA; Bos JD; Tak PP
Ann Rheum Dis; 2004 Jul; 63(7):769-73. PubMed ID: 15194570
[TBL] [Abstract][Full Text] [Related]
9. Histological evidence that infliximab treatment leads to downregulation of inflammation and tissue remodelling of the synovial membrane in spondyloarthropathy.
Kruithof E; Baeten D; Van den Bosch F; Mielants H; Veys EM; De Keyser F
Ann Rheum Dis; 2005 Apr; 64(4):529-36. PubMed ID: 15388510
[TBL] [Abstract][Full Text] [Related]
10. Clinical efficacy of infliximab plus methotrexate in DMARD naive and DMARD refractory rheumatoid arthritis is associated with decreased synovial expression of TNF alpha and IL18 but not CXCL12.
van Oosterhout M; Levarht EW; Sont JK; Huizinga TW; Toes RE; van Laar JM
Ann Rheum Dis; 2005 Apr; 64(4):537-43. PubMed ID: 15769913
[TBL] [Abstract][Full Text] [Related]
11. [Treatment of psoriatic arthritis with TNF alpha-antagonists].
Antoni C; Manger B
Z Rheumatol; 2003 Jun; 62(3):235-9. PubMed ID: 12827399
[TBL] [Abstract][Full Text] [Related]
12. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
Antoni CE; Kavanaugh A; Kirkham B; Tutuncu Z; Burmester GR; Schneider U; Furst DE; Molitor J; Keystone E; Gladman D; Manger B; Wassenberg S; Weier R; Wallace DJ; Weisman MH; Kalden JR; Smolen J
Arthritis Rheum; 2005 Apr; 52(4):1227-36. PubMed ID: 15818699
[TBL] [Abstract][Full Text] [Related]
13. Immunomodulatory effects of anti-tumor necrosis factor alpha therapy on synovium in spondylarthropathy: histologic findings in eight patients from an open-label pilot study.
Baeten D; Kruithof E; Van den Bosch F; Demetter P; Van Damme N; Cuvelier C; De Vos M; Mielants H; Veys EM; De Keyser F
Arthritis Rheum; 2001 Jan; 44(1):186-95. PubMed ID: 11212159
[TBL] [Abstract][Full Text] [Related]
14. Responsiveness to anti-tumour necrosis factor alpha therapy is related to pre-treatment tissue inflammation levels in rheumatoid arthritis patients.
van der Pouw Kraan TC; Wijbrandts CA; van Baarsen LG; Rustenburg F; Baggen JM; Verweij CL; Tak PP
Ann Rheum Dis; 2008 Apr; 67(4):563-6. PubMed ID: 18042642
[TBL] [Abstract][Full Text] [Related]
15. Intraarticular glucocorticoid treatment reduces inflammation in synovial cell infiltrations more efficiently than in synovial blood vessels.
af Klint E; Grundtman C; Engström M; Catrina AI; Makrygiannakis D; Klareskog L; Andersson U; Ulfgren AK
Arthritis Rheum; 2005 Dec; 52(12):3880-9. PubMed ID: 16320336
[TBL] [Abstract][Full Text] [Related]
16. Tumor necrosis factor alpha blockade reduces the synovial cell infiltrate early after initiation of treatment, but apparently not by induction of apoptosis in synovial tissue.
Smeets TJ; Kraan MC; van Loon ME; Tak PP
Arthritis Rheum; 2003 Aug; 48(8):2155-62. PubMed ID: 12905468
[TBL] [Abstract][Full Text] [Related]
17. Different cascades in the signaling pathway of two vascular endothelial growth factor (VEGF) receptors for the VEGF-mediated murine hepatocellular carcinoma development.
Yoshiji H; Noguchi R; Kuriyama S; Yoshii J; Ikenaka Y; Yanase K; Namisaki T; Kitade M; Yamazaki M; Uemura M; Fukui H
Oncol Rep; 2005 May; 13(5):853-7. PubMed ID: 15809749
[TBL] [Abstract][Full Text] [Related]
18. Synovial vascular patterns and angiogenic factors expression in synovial tissue and serum of patients with rheumatoid arthritis.
Salvador G; Sanmartí R; Gil-Torregrosa B; García-Peiró A; Rodríguez-Cros JR; Cañete JD
Rheumatology (Oxford); 2006 Aug; 45(8):966-71. PubMed ID: 16490752
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of VEGF receptors significantly impairs mammary cancer growth in C3(1)/Tag transgenic mice through antiangiogenic and non-antiangiogenic mechanisms.
Huh JI; Calvo A; Stafford J; Cheung M; Kumar R; Philp D; Kleinman HK; Green JE
Oncogene; 2005 Jan; 24(5):790-800. PubMed ID: 15592523
[TBL] [Abstract][Full Text] [Related]
20. Enhanced bronchial expression of vascular endothelial growth factor and receptors (Flk-1 and Flt-1) in patients with chronic obstructive pulmonary disease.
Kranenburg AR; de Boer WI; Alagappan VK; Sterk PJ; Sharma HS
Thorax; 2005 Feb; 60(2):106-13. PubMed ID: 15681497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
